ATOS Stock Analysis: Buy, Sell, or Hold?
ATOS - Atossa Therapeutics, Inc. Common Stock
$1.90
0.07 (3.83%)
▲
5d:
-19.15%
30d:
-61.77%
90d:
-66.13%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When ATOS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: ATOS is down 19.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: ATOS is down 19.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: ATOS is currently trading at $1.90, which is considered oversold relative to its 30-day fair value range of $2.71 to $5.25.
Technical Outlook: Technically, ATOS is showing sideways momentum. Immediate support is located at $1.78, while resistance sits at $4.59. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (8th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.00 (+1057.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ATOS is showing sideways momentum. Immediate support is located at $1.78, while resistance sits at $4.59. The stock is showing strong short-term momentum, up 3.8% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (8th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.00 (+1057.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.71 -
$5.25
Company Quality Score
49/100
(HOLD)
Options IV Signal
8th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
90.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 8th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.8%)
- BULLISH: Trading 1057.9% below Wall St target ($22.00)
- WARNING: Recommendation downgraded due to -19.1% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$2.71 -
$5.25
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.31
(16.2%)
Support & Resistance Levels
Support Level
$1.78
Resistance Level
$4.59
Current Trend
Sideways
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.43
Wall Street Target
$22.00
(+1057.9%)
Share & Embed Analysis
Last updated: June 24, 2026 4:51 AM ET
Data refreshes hourly during market hours. Next update: 5:51 AM
Data refreshes hourly during market hours. Next update: 5:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATOS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
|
MNMD
Mind Medicine Inc |
STRONG BUY
11 analysts |
$29 | 62 BUY |
|
ALLO
Allogene Therapeutics Inc |
STRONG BUY
14 analysts |
$8 | 60 HOLD |
